| Nivolumab plus cabozantinib versus sunitinib for advanced renal-cell carcinoma TK Choueiri, T Powles, M Burotto, B Escudier, MT Bourlon, B Zurawski, ... New England Journal of Medicine 384 (9), 829-841, 2021 | 1326 | 2021 |
| Nivolumab plus ipilimumab for metastatic castration-resistant prostate cancer: preliminary analysis of patients in the CheckMate 650 trial P Sharma, RK Pachynski, V Narayan, A Fléchon, G Gravis, MD Galsky, ... Cancer cell 38 (4), 489-499. e3, 2020 | 275 | 2020 |
| Nivolumab plus cabozantinib versus sunitinib in first-line treatment for advanced renal cell carcinoma (CheckMate 9ER): long-term follow-up results from an open-label … RJ Motzer, T Powles, M Burotto, B Escudier, MT Bourlon, AY Shah, ... The Lancet Oncology 23 (7), 888-898, 2022 | 192 | 2022 |
| 696O_PR Nivolumab+ cabozantinib vs sunitinib in first-line treatment for advanced renal cell carcinoma: First results from the randomized phase III CheckMate 9ER trial TK Choueiri, T Powles, M Burotto, MT Bourlon, B Zurawski, VMO Juárez, ... Annals of Oncology 31, S1159, 2020 | 159 | 2020 |
| Adjuvant nivolumab plus ipilimumab versus placebo for localised renal cell carcinoma after nephrectomy (CheckMate 914): a double-blind, randomised, phase 3 trial RJ Motzer, P Russo, V Grünwald, Y Tomita, B Zurawski, O Parikh, S Buti, ... The Lancet 401 (10379), 821-832, 2023 | 96 | 2023 |
| Phase II study of ipilimumab in adolescents with unresectable stage III or IV malignant melanoma B Geoerger, C Bergeron, L Gore, L Sender, IJ Dunkel, C Herzog, ... European journal of cancer 86, 358-363, 2017 | 96 | 2017 |
| Which sleep health characteristics predict all-cause mortality in older men? An application of flexible multivariable approaches ML Wallace, K Stone, SF Smagula, MH Hall, B Simsek, DM Kado, ... Sleep 41 (1), zsx189, 2018 | 94 | 2018 |
| Nivolumab+ cabozantinib (NIVO+ CABO) versus sunitinib (SUN) for advanced renal cell carcinoma (aRCC): Outcomes by sarcomatoid histology and updated trial results with extended … RJ Motzer, TK Choueiri, T Powles, M Burotto, MT Bourlon, JJ Hsieh, ... Journal of Clinical Oncology 39 (6_suppl), 308-308, 2021 | 78 | 2021 |
| Patient-reported outcomes with first-line nivolumab plus cabozantinib versus sunitinib in patients with advanced renal cell carcinoma treated in CheckMate 9ER: an open-label … D Cella, RJ Motzer, C Suarez, SI Blum, F Ejzykowicz, M Hamilton, ... The Lancet Oncology 23 (2), 292-303, 2022 | 70 | 2022 |
| Status of racial disparities between black and white women undergoing assisted reproductive technology in the US DB Seifer, B Simsek, E Wantman, AM Kotlyar Reproductive Biology and Endocrinology 18, 1-13, 2020 | 62 | 2020 |
| LBA4 Adjuvant nivolumab plus ipilimumab (NIVO+ IPI) vs placebo (PBO) for localized renal cell carcinoma (RCC) at high risk of relapse after nephrectomy: Results from the … RJ Motzer, P Russo, V Gruenwald, Y Tomita, B Zurawski, OA Parikh, ... Annals of Oncology 33, S1430, 2022 | 59 | 2022 |
| Overall survival at 5 years of follow-up in a phase III trial comparing ipilimumab 10 mg/kg with 3 mg/kg in patients with advanced melanoma PA Ascierto, M Del Vecchio, A Mackiewicz, C Robert, V Chiarion-Sileni, ... Journal for immunotherapy of cancer 8 (1), 2020 | 58 | 2020 |
| Nivolumab versus everolimus in advanced renal cell carcinoma: Japanese subgroup 3-year follow-up analysis from the Phase III CheckMate 025 study Y Tomita, S Fukasawa, N Shinohara, H Kitamura, M Oya, M Eto, K Tanabe, ... Japanese journal of clinical oncology 49 (6), 506-514, 2019 | 50 | 2019 |
| Final overall survival analysis and organ-specific target lesion assessments with two-year follow-up in CheckMate 9ER: Nivolumab plus cabozantinib versus sunitinib for patients … T Powles, TK Choueiri, M Burotto, B Escudier, MT Bourlon, AY Shah, ... Journal of Clinical Oncology 40 (6_suppl), 350-350, 2022 | 42 | 2022 |
| An approach to negative hypergeometric distribution by generatingfunction for special numbers and polynomials İ Küçükoğlu, B Şimşek, Y ŞİMŞek Turkish Journal of Mathematics 43 (5), 2337-2353, 2019 | 42 | 2019 |
| An asymptotic expansion for the normalizing constant of the Conway–Maxwell–Poisson distribution RE Gaunt, S Iyengar, AB Olde Daalhuis, B Simsek Annals of the Institute of Statistical Mathematics 71, 163-180, 2019 | 37 | 2019 |
| A phase 3, randomized, open-label study of nivolumab combined with cabozantinib vs sunitinib in patients with previously untreated advanced or metastatic renal cell carcinoma … TK Choueiri, AB Apolo, T Powles, B Escudier, OR Aren, A Shah, ... Journal of Clinical Oncology 36 (15_suppl), TPS4598-TPS4598, 2018 | 35 | 2018 |
| Nivolumab plus cabozantinib (N+ C) versus sunitinib (S) for advanced renal cell carcinoma (aRCC): Outcomes by baseline disease characteristics in the phase 3 CheckMate 9ER trial. AB Apolo, T Powles, M Burotto, MT Bourlon, JJ Hsieh, U Basso, AY Shah, ... Journal of Clinical Oncology 39 (15_suppl), 4553-4553, 2021 | 34 | 2021 |
| Generating functions for new families of combinatorial numbers and polynomials: approach to Poisson–Charlier polynomials and probability distribution function I Kucukoglu, B Simsek, Y Simsek Axioms 8 (4), 112, 2019 | 28 | 2019 |
| New classes of Catalan-type numbers and polynomials with their applications related to -adic integrals and computational algorithms İ Küçükoğlu, B Şimşek, Y ŞİMŞEK Turkish Journal of Mathematics 44 (6), 2337-2355, 2020 | 22 | 2020 |
